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ABSTRACT
Osteogenesis imperfecta (OI) is a hereditary, clinically heterogeneous, connective tissue disorder. The population prevalence of OI in
Denmark is 10.6 in 100,000. A hallmark of the disease is frequent fractures that are often precipitated by minimal trauma. The aim of
the current study was to compare the fracture rates across the lifespan of patients with OI with that of a reference population from
the general population. The present study was a Danish nationwide, population-based, cohort study using register data. We
identiﬁed 644 (55.6% females) patients in the OI cohort through the Danish National Patient Register and 3361 (55.2% females)
persons, randomly selected from the Civil Registry System. A total of 416 patients withOI experienced a total of 1566 fractures during
the observation period of median 17.9 years (interquartile range [IQR], 12.4 to 18.0 years), summing to 10137 person years. In
comparison, 709 persons in the reference population experienced a total of 1018 fractures during follow-up. Both male and female
patients with OI had an increased fracture rate throughout their life. The fracture rate ratio for participants aged 0 to 19 years was
10.7, for participants aged 20 to 54 years 17.2, and for participants aged 55 years and over 4.1 when compared to the reference
population. The highest fracture ratewas seen inmaleswithOI aged 0 to 19 years (257 fractures per 1000 person-years). The fractures
appear to follow the same pattern as in the general population, with a peak during the toddler and adolescent years (incidence rate
[IR] 233.9 per 1000 person years), fewer fractures during adulthood (IR 84.5 per 1000 person years), and increased fracture rates in
older women (IR 111.9 per 1000 person years). This is the largest register-based nationwide study on the fracture epidemiology of
patients with OI. The risk of fractures seems largest in the childhood and adolescent years, and the relative risk of fracture declines
with age in patients with OI compared to the general population. © 2016 American Society for Bone and Mineral Research.
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Introduction
Osteogenesis imperfecta (OI) is a hereditary, connectivetissue disorder caused by mutations in the genes involved
in the biosynthesis or post-transcription modiﬁcation of
collagen type 1.(1) The population prevalence of OI in Denmark
has previously been shown to be 10.6 in 100,000.(2) The clinical
severity of the disease varies from mild, with few or no signs of
the disease, to perinatally lethal phenotypes.(3)
A hallmark of the disease is frequent fractures that are often
precipitated by minimal trauma.(4) A British questionnaire study
from 1984 comprising 45 women aged 60.5 7.6 years of age
and 20 men aged 59.9 10.9 years of age, showed a peak
fracture rate of 1.6 per patient year in young men and 0.8 per
patient year in young women, fewer fractures during adult life,
and an increased fracture risk in women after menopause.(5) The
study did not include a reference group and fractures were
based on the patient’s recollection. Other studies reporting
fracture rates in patients with OI have used questionnaires,
structured interviews, or patient chart review, but did not
include a reference population.(6–8)
The unique personal identiﬁcation number issued to all
inhabitants of Denmark at birth or immigration enables individual-
level record linkagebetweendifferent health registries.(9) TheDanish
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National Patient Register (NPR)was established in 1977 and includes
primary and supplementary diagnosis for all in-hospital contacts.
Similarly, since 1995 all outpatient clinic and emergency visits have
been included in this register.(10)NPRhasacoverageabove99%, and
the overall positive predictive value of a diagnosis in the register is
above 95%.(11)Moreover, theDanish healthcare system is—with few
minor exceptions that do not apply to fracture care—uniform, tax-
ﬁnanced, and covers all residents. Together, these conditions
allow complete ascertainment and long-term follow-up of clinical
conditions.(12)
Study objectives
The aim of the current study was to compare the fracture rates
across the lifespan of patients with OI with that of the general
population. We hypothesized that patients with OI would have a
higher fracture rate than the reference population, but would
have a similar fracture pattern throughout their life. Knowledge
about fracture rates in patients with OI, under the current
treatment regimen in Denmark, will aid the physicians’ decisions
in whom and how to treat patients with OI and furthermore give
valuable information about what to expect from the current
fracture prophylaxis regimes.
Patients and Methods
The study population is a subgroup of that described in
Folkestad and colleagues (unpublished work). Mortality and
causes of death in patients with osteogenesis imperfecta. A
register-based national cohort study.
Study design
The present study is a nationwide, population-based, cohort
study using register data from Denmark.
Data source
All data were supplied with encrypted personal identiﬁcation
numbers from the Statistics Denmark Division of Research
Services Virtual Private Network (VPN) research servers (Project
reference number: 704542). The Statistics Denmark is a govern-
ment institution that provides statistics on both economic,
social and health issues and administrates most of the Danish
Health Registers.(12) Ethics committee approval was not
required. The study was approved by the Danish Data Protection
Agency. Analyses were conducted via VPN exclusively on
deidentiﬁed microdata hosted with by Statistics Denmark
with no access to subject names, social security numbers or
other identiﬁers.
Study population
The patient cohort
All patients registered in the NPR (between January 1, 1977 and
December 31, 2012) with a WHO International Classiﬁcation of
Diseases, 8th edition (ICD-8; 756.59) code or International
Classiﬁcation of Diseases, 10th edition (ICD-10; Q78.0) code for
OI were included in the study.
The reference population
For every patient with OI, ﬁve persons, matched on gender and
age (month and year of birth), were randomly selected from the
background population using the Danish Civil Registration
system. To limit the risk of misclassiﬁcation bias of the reference
population, patients could not be part of the reference
population, and the persons in the reference population could
not be ﬁrst or second degree relatives to any of the patients.
Variables and data sources
Data on bone fractures were extracted from the NPR and
included date of fracture and fracture site. The fracture groups
and corresponding ICD-10 codes are shown in Table 1.
Information on time of death was extracted from the Danish
Register of Causes of Death. Information about migration was
extracted from the Danish Civil Registration system. All data on
the reference population and the OI cohort were extracted from
the same data sources. Because the primary aim of the NPR is to
facilitate managing of Danish healthcare services, a single event
may be registered multiple times within a short period of time;
eg, a fracture could be registered from the emergency room, the
operating theater, and again from rehabilitation care.
Exposure and observation time
We counted all fractures occurring between January 1, 1995 and
December 31, 2012 (the latest updated version of the NPR at the
time of data extractionwas July 27, 2014). A personwas included
in the cohort at January 1, 1995 if born prior to this date if still
alive and living in Denmark at this date, at birth if born after
1995, or at the date of immigration to Denmark. Participants
were excluded from the cohort as of the day they died,
emigrated from Denmark, or the observation period ended.
Confounders and bias
Registration and classiﬁcation bias of fractures in the NPR
Patients with OI aremore likely to have complex fractures and to
need more hospitalization and operative treatment for their
Table 1. ICD-10 Codes Used to Group Fractures
Fracture group ICD-10 code Fracture type
Spine fractures S12 Cervical spine
S220, S221 Thoracic spine
S320 Lumbar spine
Upper arm S422, S423, S424, S427,
S428, S429
Humerus
S420 Clavicle
S421 Scapula
Forearm S52 Forearm
Hip and pelvis S720, S721, S722, S723 Hip
S32 (excluding S320) Pelvis
Femur S724, S727, S728, S729 Femur
Lower leg and
ankle
S82 Lower leg and
ankle
Other fractures S02 Head
S222 Sternum
S223, S224, S225 Ribs
S62 Hand
S92 Foot
T02 Multiple body
regions
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fractures than participants in the reference population. Because
only in-hospital care was registered in the period 1977 to 1995,
patients treated as outpatients would not be registered during
this time period. Thus, we avoided this possible bias by only
including data from the NPR from 1995, where all hospital
contacts were included in the register. Patients with OI could
also have a higher frequency of complications and re-operations
following a fracture than the reference population, thus
artiﬁcially inﬂating the fracture rates. To limit possible bias, we
introduced a 180-day “washout” period for each fracture,
whereby any new fracture with the same ICD-10 code was
ignored.
Fracture registration in the NPR does not differentiate left
from right for fractures to the appendicular skeleton. Further-
more, fractures to the axial skeleton are only differentiated by
lumbar, thoracic, and cervical fractures. This could result in
exclusion of fractures to for example the left forearm, if a fracture
had already been registered to the right forearm within the last
180 days. In patients with OI, where we would expect more
frequent fractures than in the reference population, we risk
under estimating the fracture rates. We could not correct for this
possible bias.
We recognize that the typical immobilization period after a
fracture is 40 to 60 days, and that the loss of bone and muscle
mass seen during immobilizationwill increase the refracture rate
shortly after the removal of a cast, which will result in under
reporting of refractures. This is assumed to be lower than the risk
of follow-up visit registrations with the same ICD fracture code
during the ﬁrst 180 days, which would result in inﬂation of
the fracture rates in patients needing close follow-up after a
fracture if the washout period was shorter than 180 days. Hence
the fracture rates as reported here should be regarded as
conservative.
Bisphosphonate treatment as a confounder
Since the late 1990s, patients with OI have been frequently
treated with bisphosphonates.(13) This may lower their risk of
fracture, although the effect has been questioned.(14,15)
According to national guidelines, patients with OI treated
with intravenous bisphosphonates should receive this at OI
specialist centers, but hospital-administered drugs are not
captured in the current prescription databases. The present
study captures the fracture burden to patients with OI in
Denmark given the current standard of care, which may or may
not be lower than would be the case had the disease been
allowed to take its natural course in all patients.
Fracture risk due to differences in age and gender
We have intentionally corrected for differences in fracture risk at
different ages and between genders by matching the reference
population to the OI cohort on age and gender.
Immortal time bias
To reduce the risk of immortal time bias (ie, the time during
which a participant could suffer an event that would not be
registered), we ended the observation period at the date of
emigration. Patients experiencing fractures while travelling
abroad would normally receive subsequent fracture care in
Denmark and in most cases be captured in the registers.
Statistical analysis
All statistical analyses were done using Stata 14.1 (StataCorp,
College Station, TX, USA).
Data are presented as mean SD or median (interquartile
range [IQR]or range) as appropriate. Fracture rates (incidence rate
[IR]) are presented as number of fractures per 1000 person years
for each group and gender. We calculated the 95% conﬁdence
interval (CI) as IR (1.96  IR/ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃtotal number of fracturesp ). Inci-
dence rate ratios (IRRs) between patients with OI and the
referencepopulationwere considered signiﬁcant if the 95%CIdid
not include the value 1. For illustrative purposes, we calculated
the IR and 95% CI for fractures in 5-year age bands (Fig. 1,
Supporting Table 1).
The association between OI (yes, no) and fracture rates
adjusted for differences in gender and age was evaluated using
a Poisson regressionmodel with total number of fractures as the
outcome variable, and logarithmic transformation of follow-up
time within each age strata and calendar year as offset. Age
groups were 0 to 19 years (to include fractures due to falls when
toddlers and young children become more mobile, and the
increased fracture risk during growth spurts in puberty and
adolescents), 20 to 54 years (adult life), and 55 years and above
(to include the increased fracture risk due to postmenopausal
bone loss for women and age-related bone loss in men). The
relatively large age bands were used to ensure sufﬁcient events
for statistical power to calculate the IRR between the OI cohort
and the reference population. As we expected an interaction
between age, gender, and OI, we introduced an three-way
interaction term. We used the likelihood ratio test to identify
statistically signiﬁcant interactions, accepting a p value<0.05 as
statistically signiﬁcant. The independent variables in the ﬁnal
model were OI, age, gender, and the interaction term.
To control for any period effect, ie, the reduction in fracture
rates caused by the introduction of bisphosphonates to treat
patients at high risk of fracture, we included calendar year as an
independent variable in the initial model. This variable was not
signiﬁcant, however, and was not included in the ﬁnal model.
We used Pearson’s goodness-of-ﬁt to evaluate model ﬁt.
The analyses were stratiﬁed by the seven fracture diagnosis
groups as described in Table 1. We ran individual models for
each fracture group to calculate the IRR between patients with
OI and the reference population of different fracture types over
time.
We performed four sensitivity analyses to evaluate (1) the
effect of the washout time for counting a new fracture at the
same site—by removing the washout period from the NPR data;
(2) the effect of the 180-day washout period—by using a 365-
day washout instead; (3) the effect of including patients with
only a referral diagnosis of OI registered in the NPR; and (4) the
effect of suspectedmore severe phenotypes, deﬁned as patients
dying before the age of 10 years. We recognize that the majority
of patients with moderate to severe phenotypes will live past
the age of 10 years. A sensitivity analysis was performed as we
assumed that patients who die before 10 years old would have
the most severe phenotypes of OI and would theoretically have
a much higher fracture rate than the general OI population.
Ethical considerations
The study was approved by the Danish Data Protection Agency.
All data were deidentiﬁed by Statistics Denmark before being
made accessible for analysis. The studywas not eligible for ethics
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committee approval, nor was it a clinical trial. To avoid
identiﬁcation of conﬁdential participant information we do
not show results if the total number of events is lower than three.
Results
We identiﬁed 687 patients with OI from the NPR in 1977 to 2012,
of whom 379 (55.2%) were females. Excluding all censored
participants prior to 1995 (participants who had died or
migrated prior to January 1, 1995), the OI cohort included 644
(55.6% females) patients and the reference population 3361
(55.2% females) persons for analysis (Table 2). During the period
2002 to 2013, 14 patients withmedian age 5.5 years (IQR, 2 to 12)
were registered with a referral diagnosis of OI alone; ie, they did
not have an outpatient or a hospital discharge OI diagnosis
registered in the NPR. Six participants died before their 10th
birthday during the observation period, with median age 0.2
years (range, 0 to 7.2). None of the reference population died in
this age interval. The participants were followed for a median of
17.9 years (IQR, 12.6 to 18.0 years). Median age at the start of the
observation was 15.0 years (range, 0 to 71 years) for the OI
cohort and 15.0 years (range, 0 to 81 years) for the reference
population.
Fracture rate in the OI cohort and the reference
population
Figure 1 (and Supporting Table 1) shows the fracture rates for
the OI cohort and the reference population in 5-year age groups.
Of the 644 patients with OI, 416 experienced a total of 1566
fractures during the observation period. The median number of
fractures was 1 per patient (range, 0 to 25 per patient),
amounting to 0.15 fractures per person year. In the reference
population, 709 persons experienced at least one fracture
during the observation time, with a total of 1018 fractures. The
median number of fractures was 0 per person (range, 0 to 9 per
person). Comparing the patients with OI and the reference
population the fracture IRR was 8.1 (95% CI, 7.5 to 8.8). Analyzing
the data according to three age groups, we found the fracture
IRR for persons aged 0 to 19 years was 10.7, for persons aged 20
to 54 years was 6.2, and for persons aged 55 years and over was
4.1 (Table 3). The fracture rate was higher in postmenopausal
women than in men over 55 years—this was the case for both
patients with OI (IRR 1.6; 95% CI, 1.1 to 2.4) and for the reference
population (IRR 2.1; 95% CI, 1.5 to 2.9). Among participants aged
55 years and over, women with OI had higher fracture rates than
women in the reference population (IRR 8.0; 95% CI, 5.6 to 11.3),
and men with OI had higher fracture rates than men in the
reference population (IRR 4.9; 95% CI, 3.2 to 7.7).
Fracture sites
As shown in Table 4, the most frequent fracture sites in patients
with OI were forearm, femur, and lower leg and ankle (see also
Fig. 2 for females and Fig. 3 for males). Within the OI cohort,
males aged 0 to 19 years had the highest rates of most fractures
compared to middle-aged and older men. Among older (55þ
years) patients with OI, women had a higher fracture rate than
men of fractures in the upper arm, forearm, hip and pelvis, and
lower leg and ankle. These fracture rates for older women with
OI were higher than those for younger (20 to 55 years) women
with OI. In the reference population, fracture rates for most
fracture sites were highest for men and women aged 55 years
and over.
Sensitivity analysis
The total number of fracture registrations in the NPR was higher
when double registrations and readmissions were not excluded.
The total number of fracture registrations in the NPRwas 3441 in
the OI cohort and 1772 in the reference population (IRR 7.9; 95%
CI, 7.5 to 8.4). When a 365-day washout period was used instead
of a 180-day period, the number of fracture registrations in the
NPR was 980 in the OI cohort and 930 in the reference
population (IRR 4.3; 95% CI, 4.0 to 4.8). No signiﬁcant changes in
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Fig. 1. Fracture rate in the OI cohort and the reference population by age, for males and females separately. Fracture rate is highest in the youngest
patients with OI and then decreases during adult life. Especially in the reference population, the rate increases in women of postmenopausal age. The
two groups were fully matched for age but shown here with a small offset on the x axis to provide space for conﬁdence interval bars.
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the IRR between the OI cohort and the reference population
were seen when we excluded the 14 patients with only a referral
diagnosis, or the six patients who died before the age of
10 years.
Discussion
In this register-based cohort study, male and female patients
with OI had an increased fracture rate throughout their life,
compared to the reference population. The highest fracture rate
was seen in males with OI aged 0 to 19 years (257 fractures per
1000 person-years). Our study included 644 patients and
appears to be the largest published population-based study
aimed at evaluating fracture rates in patients with OI.
Throughout the observation period, the mean fracture rate in
the OI cohort was 154.5 fractures per 1000 person years, or an
annual rate of 0.15 per patient. In a Swedish study where
fractures were determined from patients’ medical charts, the
annual fracture rate was 0.57 for patients with type I (n¼ 151,
aged 22.4 16.9 years), 3.83 for patients with type III (n¼ 29,
aged 22.6 18.7 years), and 1.33 for patients with type IV
(n¼ 42, aged 19.6 12.0 years).(8) A cross-sectional multicenter
study of OI in North America that included 544 patients with a
median age at inclusion at 12.6 years (range, 0 to 67 years)
reported an average of 1.0 3.0 fractures per individual in the
year prior to enrolment.(7) Our data are more similar to a
Norwegian population-based cohort study that included all
known adult patients with OI, with a mean age of 44 12 years
(range, 25 to 83) at enrollment.(6) The authors reported an
annual rate of 0.12 fractures per individual in the year prior to
enrollment in the study.(6)
We acknowledge that our estimates of fracture rates may be
conservative. This may be partly due to using the 180-day
washout period before counting a fracture to the same
anatomical site as a new fracture, and simultaneously not
counting fractures to the contralateral anatomical site. This is a
limitation to our study. However, the sensitivity analysis showed
that evenwith nowashout the IRRwould be similar between the
two groups. Patients with OI may have more frequent
complications and reoperations than the reference population,
and thus we may have inﬂated their fracture rates had we not
stipulated a reasonable long washout period. Some fracture
types are likely to be underreported in the registries, such as
spinal fragility fractures that often do not result in radiographs or
hospitalization and could even be asymptomatic in the short
term. No data are available on the positive and negative
predictive value of the NPR for symptomatic spine fractures.
However, the register-based incidence of symptomatic spine
fractures in Denmark in 2011 was 4.3 times lower than the
incidence reported by the International Osteoporosis Founda-
tion, whichwas based on radiographic data.(16) Furthermore, in a
1982 Danish study, 52 of 289 seventy-year-old women had
experienced at least one spine crush fracture when evaluated
by radiographs.(17) This is much higher than what we found via
the Danish health registers. Vertebral fractures are frequent in
patients with OI. In a study including 97 adult patients with OI
using radiographs in the anteroposterior and lateral positions to
evaluate the spine, 67% had at least one vertebral deformity,
Table 2. Characteristics of the Patient Cohort With OI and the
Reference Group From the General Danish Population
OI cohort
Reference
population
Number of participants, n 644 3361
Female participants, n, (%) 358 (56) 1854 (55)
Participants aged 0–20, n 416 2171
Participants aged 20–55, n 352 1802
Participants aged above 55, n 140 774
Total participation time (years) 10137 53328
Median observation time per
individual (years)
17.9 (IQR,
12.4–18.0)
17.9 (IQR,
12.7–18.0)
Median age at end (years) 32.6 (IQR,
15.3–51.3)
32.2 (IQR,
16.0–52.5)
Total number of fractures, n 1566 1018
Because some of the participants could feature in more than one age
strata, the numbers do not add to the total number of participants.
OI¼ osteogenesis imperfecta; IQR¼ interquartile range.
Table 3. Comparison of Fracture Rates by Age Group in the OI cohort and the reference population
OI cohort Reference population
Fractures (n)
Person-years
at risk
IR per 1000
person years
(95% CI) Fractures (n)
Person
years at risk
IR per 1000
person years
(95% CI)
IRR
(95% CI)
All
0–19 years 1078 4610 233.9 (219.9–247.8) 531 24265 21.9 (20.0–23.7) 10.7 (9.6–11.9)
20–54 years 338 3988 84.8 (75.7–93.8) 277 20329 13.6 (12.0–15.2) 6.2 (5.3–7.3)
55þ years 150 1540 97.4 (81.8–113.0) 210 8735 24.0 (20.8–27.3) 4.1 (3.3–5.0)
Females
0–19 years 515 2421 212.7 (194.3–231.1) 219 12403 17.7 (15.3–20.0) 12.1 (10.3–14.1)
20–54 years 160 2351 68.1 (57.5–78.6) 134 11617 11.5 (9.6–13.5) 5.9 (4.7–7.4)
55þ years 114 1019 111.9 (91.3–132.4) 168 5745 29.2 (24.8–33.7) 8.0 (5.6–11.4)
Males
0–19 years 563 2188 257.3 (236.0–278.5) 312 11862 26.3 (23.4–29.2) 9.8 (8.5–11.2)
20–54 years 178 1637 108.7 (92.8–124.7) 143 8712 16.4 (13.7–19.1) 6.6 (5.3–8.2)
55þ years 35 521 69.1 (46.6–91.7) 42 2988 14.1 (9.8–18.3) 4.9 (3.2–7.7)
Because some of the participants could feature in more than one age strata, the numbers do not add to the total number of participants.
OI¼ osteogenesis imperfecta; IR¼ incidence rate; IRR¼ incidence rate ratio (calculated using a Poisson regression model).
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Table 4. Fracture Rates in the OI Cohort and Reference Population by Fracture Site and Age Group, for Men and Women Separately
OI cohort Reference population
Person years
at risk
Fractures
(n)
IR per 1000
person years
(95% CI)
Person years
at risk
Fractures
(n)
IR per 1000
person years
(95% CI)
IRR
(95% CI)
Females
Upper arm fractures
0–19 years 2421 63 26.0 (19.6–32.5) 12403 25 2.0 (1.2–2.8) 12.9
(8.1–20.5)
20–54 years 2351 11 4.7 (1.9–7.4) 11617 15 1.29 (0.6–1.9) 3.6 (1.7–7.9)
55þ years 1019 19 18.7 (10.3–27.0) 5745 24 4.17(2.5–5.6) 4.5 (2.4–8.2)
Forearm fractures
0–19 years 2421 125 51.6 (42.7–60.7) 12403 75 6.1 (4.7–7.4) 8.4
(6.3–11.4)
20–54 years 2351 25 10.6 (6.47–14.8) 11617 27 2.3 (1.5–3.2) 9.3
(4.6–18.9)
55þ years 1019 23 22.6 (13.3–31.8) 5745 48 8.3 (6.0–10.7) 5.7
(1.9–17.8)
Spine fractures
0–19 years 2421 5 1.6 (0.5–2.6) 12403 4 0.3 (0.0–0.6) 6.4
(1.7–23.9)
20–54 years 2351 9 2.1 (0.3–3.9) 11617 —a NA NA
55þ years 1019 4 3.9 (0.1–7.8) 5745 9 1.6 (0.5–2.6) 2.5 (0.8–8.1)
Hip fractures
0–19 years 2421 19 7.8 (4.3–11.4) 12403 —a NA NA
20–54 years 2351 8 3.4 (1.0–5.8) 11617 5 0.4 (0.1–0.8) 7.9
(2.6–24.2)
55þ years 1019 14 13.7 (6.5–20.9) 5745 26 4.52 (2.79–6.26) 3.4(1.6–5.8)
Femur fractures
0–19 years 2421 86 35.52 (28.01–43.03) 12403 —a NA NA
20–54 years 2351 17 7.2 (3.8–10.7) 11617 —a NA NA
55þ years 1019 9 8.8 (3.1–14.6) 5745 18 1.7 (0.7–2.8) 5.1
(2.1–12.5)
Lower leg and ankle
0–19 years 2421 89 36.8 (29.1–44.4) 12403 15 1.2 (0.6–1.8) 30.4
(17.6–52.5)
20–54 years 2351 26 11.1 (6.8–15.3) 11617 22 1.9 (1.1–2.7) 5.8
(3.3–10.3)
55þ years 1019 18 17.7 (9.5–25.8) 5745 14 2.4 (1.2–3.7) 7.3
(3.6–14.6)
Other fractures
0–19 years 2421 128 52.9 (43.7–62.0) 12403 99 8.0 (6.4–9.6) 6.6 (3.6–5.6)
20–54 years 2351 64 27.2 (20.6–33.9) 11617 63 5.4 (4.1–6.8) 5.0 (3.6–7.1)
55þ years 1019 27 26.5 (16.5–36.5) 5745 37 6.4 (4.4–8.5) 4.1 (2.5–6.8)
Males
Upper arm fractures
0–19 years 2188 63 28.8 (21.7–35.9) 11862 37 3.1 (2.1–4.1) 9.2
(6.2–13.9)
20–54 years 1637 16 9.8 (5.0–14.6) 8712 17 2.0 (1.0–2.9) 5.0 (2.5–9.9)
55þyears 521 6 11.5 (2.3–20.7) 2989 3 1.0 (–0.1 to 2.1) 11.5
(2.9–45.9)
Forearm fractures
0–19 years 2188 109 49.8 (40.5–59.2) 11862 70 5.9 (4.5–7.3) 8.5
(6.4–11.4)
20–54 years 1637 21 12.8 (7.3–18.3) 8712 12 1.4 (0.6–2.2) 9.3
(4.6–18.9)
55þyears 521 6 11.5 (2.3–20.7) 2989 6 2.0 (0.4–3.6) 5.7
(1.9–17.8)
Spine fractures
0–19 years 2188 10 4.6 (1.7–7.4) 11862 3 0.3 (–0.3 to 0.5) 8.4
(6.3–11.4)
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most frequently in the mid-thoracic region.(18) The spinal
fracture prevalence was lowest in patients with OI type I and
highest in patients with OI type III.(18) We acknowledge that we
will underestimate the rates of vertebral fractures using a
register-based approach, as vertebral fractures are known to be
underreported by most healthcare systems.
Fracture rates across the lifespan
Our patients with OI had the highest fracture rate during their
ﬁrst two decades of life. We saw the highest rates of forearm,
femur, and lower leg and ankle fractures in the youngest age
group. This indicates that children with OI are likely to be more
susceptible to long-bone fractures when they start to walk and
becomemore active. In a British study of childhood fractures, the
peak fracture rates were at age 11 to 15 years.(19) The skeleton
adapts to the need of increased bone strength in the growing
skeleton, but there seems to be a lag in bone strength during
periods of accelerated growth as seen during the pubertal
growth spurt.(20) We speculate that the disconcordance in bone
strength and growth could explain some of the increased
fracture rates seen in patients with OI during the ﬁrst two
decades of life.
Although several fracture types showed increased IRR among
women with OI aged 55 years and over, IRR was lower in men
with OI in this age group. However, this may be due to the low
number of older men in our cohort as a result of higher
mortality.(21) Patients with the most severe phenotypes of OI
will have increased risk of early death(22); this could lead to a
positive selection of patients with milder phenotypes, and
thus fewer fractures, in the older age strata.
In postmenopausal women with OI the fracture rate was
almost twice as high as that of premenopausal women. Also,
the IRR was 8.0 (95% CI, 5.6 to 11.4) between OI cohort
postmenopausal women and the reference population women,
suggesting that bone loss associated with menopause has an
important role in the fracture risk of OI patients. Paterson and
colleagues(5) reported increased fracture rates after menopause,
with the highest being 0.5 fractures per patient year at 25 years
after menopause.
Effect of bisphosphonate use on fracture rates
We had no data on bisphosphonate use in our cohort, butwe did
not see a period effect when we entered calendar year into our
Poisson model, as would be expected had the prognosis of
fractures suddenly improved with the more widespread use of
bisphosphonates in the late 1990s. In a Cochrane review(15) that
included randomized studies with young patients with OI, the
authors saw little evidence of fracture prevention by bi-
sphosphonates. In contrast, a meta-analysis including random-
ized studies on adult patients showed a reduced fracture rate
Table 4. (Continued )
OI cohort Reference population
Person years
at risk
Fractures
(n)
IR per 1000
person years
(95% CI)
Person years
at risk
Fractures
(n)
IR per 1000
person years
(95% CI)
IRR
(95% CI)
20–54 years 1637 5 3.1 (0.4–5.7) 8712 3 0.3 (–0.1 to 0.7) 9.3
(4.6–18.9)
55þyears 521 3 5.8 (0.8–12.3) 2989 —a NA NA
Hip fractures
0–19 years 2188 20 9.1 (5.1–13.1) 11862 —a NA NA
20–54 years 1637 9 5.5 (1.9–9.1) 8712 2 0.2 (–0.1 to 0.5) 24.0
(5.2–110.9)
55þ years 521 4 7.7 (0.2–15.2) 2989 13 4.4 (2.0–6.7) 1.8 (0.6–5.4)
Femur fractures
0–19 years 2188 91 41.6 (33.0–50.1) 11862 3 0.3 (–0.3 to 0.5) 164.4
(52.1–519.2)
20–54 years 1637 12 7.3 (3.2–11.5) 8712 —a NA NA
55þyears 521 4 7.7 (0.2–15.2) 2989 —a NA NA
Lower leg and ankle
fractures
0–19 years 2188 135 61.7 (51.3–72.1) 11862 35 3.0 (2.0–3.9) 20.9
(14.4–30.3)
20–54 years 1637 37 22.6 (15.3–29.9) 8712 18 2.1 (1.1–3.0) 10.9
(6.2–19.2)
55þyears 521 5 9.6 (1.2–18.0) 2989 5 1.7 (0.2–3.1) 5.7
(1.7–19.8)
Other fractures
0–19 years 2188 135 61.7 (51.3–72.1) 11862 164 13.8
(11.71–15.9)
4.5 (3.6–5.6)
20–54 years 1637 78 47.6 (37.1–58.2) 8712 91 10.5 (8.3–12.6) 4.6 (3.4–6.2)
55þ years 521 8 15.4 (4.7–26.0) 2989 13 4.4 (2.0–6.7) 3.5 (1.5–8.5)
OI¼ osteogenesis imperfecta; IR¼ incidence rate; IRR¼ incidence rate ratio (calculated using a Poisson regression model); NA¼not applicable.
aDue to a very low number of fractures, the number is not provided (and the IRR not calculated) to avoid identiﬁcation of conﬁdential participant
information.
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during bisphosphonate treatment (Relative Risk 0.71; 95% CI,
0.52 to 0.96).(14) The authors concluded, however, that the
evidence for fracture prevention with bisphosphonates was
weak due to underpowered and heterogeneous studies.(14) The
rates reported in the present study are representative of the
burden of fractures in Danish patients with OI under the current
standard of care in the country, including the potential use of
bisphosphonate treatment.
Fracture reporting and information on OI subtypes
Clinical experience shows that some patients with OI experience
fractures so frequently that they sometimes treat fractures
themselves by self-immobilizing and analgesics. This could
potentially lead to underreporting of fractures in our study,
because we only have access to information on fractures treated
by the hospital. Thus, our data may reﬂect the fracture burden
posed to the healthcare system and not necessarily that
experienced by the patient. The extent of undertreatment is
unknown, butwemustconsider thepossibility that theproportion
of self-treated fractures may be larger in the more severe
phenotypes than in the milder phenotypes. The reliability of
fracture records in the NPR is generally high, with a concordance
of 94% for hip, 84% for forearm, and 83% for humerus in self-
reported fractures among Danish female nurses.(23) However,
this has not been tested speciﬁcally for OI patients.
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A major limitation to our study is the lack of data on clinical
or genetic OI subtypes in our population. There is signiﬁcant
overlap between clinical phenotypes of OI, and for the more
severe phenotypes (II to XV) genotypic information can be used
to classify the patients within these forms of OI.(1) In the
Norwegian population-based study, the patients with type I OI
reported to have suffered between 1 and 170 fractures since
birth, and patients with the more severer forms of OI (types III to
IV) reported having suffered four to 300 fractures since birth.(6)
Dataon fractureswerecollected througha structured interview.(6)
This method of fracture assessment is prone to recall bias
among patients. In a sensitivity analysis excluding the six patients
thought to suffer from the most severe phenotypes in our
study, we saw no signiﬁcant change in the fracture rates in
the OI population. In a population of 644 patients, at least
120 patients would be expected to have moderate to severe OI.
The fracture rates in these patients will be underestimated.
The life expectancy in patients with moderate OI phenotypes
is lower than the general population, but in 1996, Paterson
and colleagues(24) found that the remaining life expectancy
in patients with a moderate phenotype of OI was 72 years in
women and 69 years in men at birth. A substantial portion of
patients with moderate to severe phenotypes will survive into
adulthood.
Validity of the OI diagnosis
We had no data on the speciﬁcity, sensitivity, or positive/
negative predictive value of having an ICD-8 or ICD-10
diagnosis for OI in the NPR. A Danish study from 1989
estimated the prevalence of OI in the Danish population to be
10.6 per 100,000 persons.(2) Because the population of
Denmark in 2012 comprised 5,230,310 citizens, we would
have expected to identify 554 patients and we identiﬁed 687
persons with OI, of whom 112 died during the observation
period, leaving 575 patients in the population. Thus it is likely
that we have identiﬁed most patients with OI in Denmark. In a
Danish study, 91 patients registered with an OI diagnosis
in hospital treatment databases (which should reﬂect what
is reported to the NPR) were clinically evaluated. An OI
diagnosis could not be conﬁrmed in six of these patients.(25)
Three patients had idiopathic familial osteoporosis and
three patients were ﬁrst-degree relatives to patients with OI
but had themselves too few classic OI symptoms to allow
the authors to accept the registered OI diagnosis in the
hospital treatment databases.(25) We saw no signiﬁcant
change in the IRR between patients with OI and the reference
population when we omitted patients with only a referral
diagnosis for OI. Misclassiﬁcation bias cannot be ruled out, but
if non-OI patients had been included in the OI cohort, it would
lead to a false reduction in the ratio between the OI cohort
and the reference population.
Our study had several strengths. It was population-based and
included all patients registered with an OI diagnosis. Patients
were identiﬁed via high-quality national databases on hospital
discharges, outpatient clinic visits, and emergency department
visits. Furthermore, fracture data for the patient and the
reference populations were collected from the same databases,
and were not prone to recall bias in the same way as self-report
and interview data.
We conﬁrm that patients with OI have increased risk of
fractures throughout their life compared to the general
population. Though the relative risk declines with age, fractures
as a whole appear to follow the same pattern in terms of
absolute rates as that of the general population, with a peak
fracture rate during the toddler and adolescent years (IR 233.9
per 1000 person years), fewer fractures during adulthood (IR 84.5
per 1000 person years), and increased fracture rates in older
women (IR 111.9 per 1000 person years).
Disclosures
All authors have completed the ICMJE uniform disclosure form at
www.imcje.org/coi_disclosure.pdf and declare no support from
any organization for the submittedwork. LF received speaker fees
fromGenzymes, a Sanoﬁ Company, andAstraZeneca; JH received
speaker fee from Amgen; BL serves on advisory boards for Merck,
Eli Lilly, Amgen, and UCB, she has received speaker fees from
Amgen,Merck, and Eli Lilly and she has received research funding
fromNovoNordisk, Eli Lilly, andOrkla. JG serves onadvisoryboard
for Merck, and Novo Nordisk. APH serves on advisory boards for
Merck, Eli Lilly, Amgen, and Shire, and she has received research
funding from Eli Lilly, speaker fee from Eli Lilly, GSK, Genzyme,
Amgen; BA reports grants from Novartis (current), personal fees
from Nycomed/Takeda (past, within 36 months), personal fees
from Merck (past, within 36 months), personal fees from Amgen
(past, within 36 months), grants from UCB (current), outside the
submitted work; KB reports other from Merck, Sharpe, Dohme,
other from Amgen, other from Novartis, other from NPS, outside
the submitted work.
Acknowledgments
We acknowledge Claire Gudex for proofreading and editing of
an earlier version of this manuscript.
Authors’ roles: All authors contributed to the design of the
study, the interpretation of the results, and reviewed the
manuscript. LF performed the statistical analysis and is
guarantor for the study. LF wrote the ﬁrst draft of the
manuscript. All authors accepted the ﬁnal version of the
manuscript.
References
1. Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016;387:
1657–71.
2. Andersen PE Jr, Hauge M. Osteogenesis imperfecta: a genetic,
radiological, and epidemiological study. Clin Genet. 1989;36:
250–5.
3. Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis,
nomenclature and severity assessment. Am J Med Genet A. 2014;
164A:1470–81.
4. Fratzl-Zelman N, Misof BM, Klaushofer K, Roschger P. Bone mass and
mineralization in osteogenesis imperfecta. Wien Med Wochenschr.
2015;165:271–7.
5. Paterson CR, McAllion S, Stellman JL. Osteogenesis imperfecta after
the menopause. N Engl J Med. 1984;310:1694–6.
6. Wekre LL, Eriksen EF, Falch JA. Bone mass, bone markers and
prevalence of fractures in adults with osteogenesis imperfecta. Arch
Osteoporos. 2011;6:31–8.
7. PatelRM,NagamaniSC,CuthbertsonD,etal.Across-sectionalmulticenter
study of osteogenesis imperfecta in North America—results from the
linked clinical research centers. Clin Genet. 2015;87:133–40.
8. Lindahl K, AstromE, RubinCJ, et al. Genetic epidemiology, prevalence,
and genotype-phenotype correlations in the Swedish population
with osteogenesis imperfecta. Eur J Hum Genet. 2015;23:1042–50.
Journal of Bone and Mineral Research FRACTURE RATES IN OSTEOGENESIS IMPERFECTA 133
9. Pedersen CB. The Danish Civil Registration System. Scand J Public
Health. 2011;39:22–5.
10. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient
Register. Scand J Public Health. 2011;39:30–3.
11. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT.
The predictive value of ICD-10 diagnostic coding used to assess
Charlson comorbidity index conditions in the population-based
Danish National Registry of Patients. BMC Med Res Methodol.
2011;11:83.
12. Thygesen LC, Daasnes C, Thaulow I, Bronnum-Hansen H. Introduc-
tion to Danish (nationwide) registers on health and social issues:
structure, access, legislation, and archiving. Scand J Public Health.
2011;39:12–6.
13. Lindahl K, Langdahl B, Ljunggren O, Kindmark A. Treatment of
osteogenesis imperfecta in adults. Eur J Endocrinol. 2014;171:
R79–90.
14. Hald JD, Evangelou E, Langdahl BL, Ralston SH. Bisphosphonates
for the prevention of fractures in osteogenesis imperfecta: meta-
analysis of placebo-controlled trials. J Bone Miner Res. 2015;30:
929–33.
15. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for
osteogenesis imperfecta. Cochrane Database System Rev. 2014 Jul
23;(7):CD005088.
16. Driessen JH, Hansen L, Eriksen SA, et al. The epidemiology of
fractures in Denmark in 2011. Osteoporos Int. 2016;27:2017–25.
17. Jensen GF, Christiansen C, Boesen J, Heged€us V, Transbøl I.
Epidemiology of postmenopausal spinal and long bone fractures.
A unifying approach to postmenopausal osteoporosis. Clin Orthop
Relat Res. 1982 Jun;(166):75–81.
18. Wekre LL, Kjensli A, Aasand K, Falch JA, Eriksen EF. Spinal deformities
and lung function in adults with osteogenesis imperfecta. Clin Respir
J. 2014;8:437–43.
19. Cooper C, Dennison EM, Leufkens HG, Bishop N, van Staa TP.
Epidemiology of childhood fractures in Britain: a study using the
general practice research database. J Bone Miner Res. 2004;19:
1976–81.
20. Rauch F, Schoenau E. The developing bone: slave or master of its
cells and molecules? Pediatr Res. 2001;50:309–14.
21. Folkestad L, Hald JD, Canudas-Romo V, et al. Mortality and causes of
death in patients with osteogenesis imperfecta. A register-based
nationwide cohort study. J BoneMiner Res. Forthcoming. Epub 2016
Jul 18. DOI:10.1002/jbmr.2895.
22. McAllion SJ, Paterson CR. Causes of death in osteogenesis imperfecta.
J Clin Pathol. 1996;49:627–30.
23. Hundrup YA, Hoidrup S, Obel EB, Rasmussen NK. The validity of self-
reported fractures among Danish female nurses: comparison with
fractures registered in the Danish National Hospital Register. Scand J
Public Health. 2004;32:136–43.
24. Paterson CR, Ogston SA, Henry RM. Life expectancy in osteogenesis
imperfecta. BMJ. 1996;312:351.
25. Hald JD, Folkestad L, Harsløf T, et al. Skeletal phenotypes in
adult patients with osteogenesis imperfecta-correlations with
COL1A1/COL1A2 genotype and collagen structure. Osteoporos
Int. Forthcoming. Epub 2016 Jun 2. DOI:10.1007/s00198-016-3653-0.
134 FOLKESTAD ET AL. Journal of Bone and Mineral Research
